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BACKGROUND: In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS).
METHODS: In this report, we present the results of a phase II trial of FOLFOX6þbevacizumab in patients with non-optimally
resectable CLM. Patients received six cycles of FOLFOX6þ five of bevacizumab. Patients not achieving resectability received six
additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment.
RESULTS: From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective
response (OR) was documented in 12 cases (57.1%; complete responses (CRs): 3, partial response (PR): 9); one patient died from
toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients
(46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months.
Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS)
(median PFS: 22 vs 14 months, P¼0.001).
CONCLUSIONS: FOLFOX6þbevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early
changes in PET-CT seem to be predictive of longer PFS.
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Resection of metastases is the optimal treatment goal in metastatic
colorectal cancer. In particular, approximately 50% of patients
with colorectal cancer will develop metastases (synchronous or
metachronus) during their clinical history and 30–35% will have
liver metastases only. Only 10–20% of patients are candidates for
surgery, whereas the remainder are candidates for only palliative
treatment. In resectable patients, the cure rate is about 20–30%,
with a survival rate of 40%, but 70–80% will relapse within 2 years
(Chua and Cunningham, 2006; Van Cutsem et al, 2006).
Surgery may lead to long-term survival: on the basis of the
Oncosurge international registry of patients operated on for colorectal
liver metastasis (http://www.livermetsurvey.org, 2009), the 5- and
10-year post-hepatectomy survival rates are 40 and 25%, respectively.
Adam et al reported a 13% rate of conversion to resectability for
patients with unresectable disease after tumour downsizing by
chemotherapy, associated with a 5-year survival rate of 33% after
hepatectomy. Moreover, the 10-year long-term survival of liver
resection for primarily resectable patients is 30 vs 23% for patients
with initially unresectable metastases that become resectable after
chemotherapy (Adam et al, 2004).
Although there is consensus on the role of surgery in CLM, the
best neoadjuvant chemotherapy is still not clear. In general,
chemotherapy should aim to achieve a higher response rate, to be
clinically manageable and to have minimal toxicity.
There is a strong correlation between response rates and the
resection rate, both in patients selected for liver metastases only,
and in non-selected patients; however, patient selection and
efficacy of neoadjuvant chemotherapy are both strong predictors
for resectability of CLM (Folprecht et al, 2005).
Numerous combination therapies have been tested in this
setting: doublets, doublets plus biologics, triplets and triplets plus
biologics (early results), with a response rate of 34–80% and a
resectability rate of 2–92% (depending on patient selection)
(Tournigand et al, 2004; Falcone et al, 2007; Gruenberger et al,
2008; Bokemeyer et al, 2009; Okines et al, 2009; Van Cutsem et al,
2009; Wong et al, 2009; Folprecht et al 2010; Masi et al, 2010).
Moreover, when the present study was planned, the use of
bevacizumab in the neoadjuvant setting was limited by the
potential for mechanism of action-based increase of postoperative
morbidity from haemorrhagic complications and delay of wound
healing.
Therefore, we designed this phase II trial to estimate the
percentage of patients amenable to complete resection after
3 months of neoadjuvant combination therapy with FOLFOX6þ
bevacizumab.
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This phase II study was designed and conducted according to
the International Conference on Harmonisation Harmonized
Tripartite Guideline for Good Clinical Practice (http://www.ifpma.
org/pdfifpma/e6.pdf). The protocol was approved by the Local
Ethics Committee of the Province of Modena, Italy.
Eligibility criteria
Eligible patients were aged X18 years with a histologically or
cytologically proven diagnosis of colorectal cancer with non-
optimally resectable liver metastases that are evaluable according
to RECIST criteria and not previously treated with chemotherapy
for metastatic disease. Non-optimally resectable was defined as:
single nodule (45cm); multiple nodules (44cm) and/or bilobar
lesions; synchronous liver metastases (especially for patients with
rectal cancer). Moreover, patients had to have an Eastern
Cooperative Oncology Group Performance Status of 0–1 and
adequate organ function: neutrophils X1.5 10
9l
 1, platelets
X100 10
9l
 1, and haemoglobin X9gdl
 1, bilirubin level of
normal or o1.5 upper limit of normal (ULN) of the Institutional
normal values, aspartate aminotransferase and/or alanine amino-
transferase p5 ULN, alkaline phosphatase, p5 ULN, serum
creatinine o1.5 ULN, urine dipstick of proteinuria o2þ
(patients with proteinuria on baseline dipstick urinalysis X2þ
had to undergo a 24-h urine collection and must have had p1gof
protein per 24h); signed informed consent was required before
beginning protocol-specific procedures. Patients had to have a life
expectancy of at least 12 weeks and be accessible for treatment and
follow up.
Exclusion criteria
Patients were excluded for unresectable extra-hepatic disease;
evidence of peritoneal carcinosis at baseline; widespread liver
involvement (470–80%); symptomatic and/or unstable pre-
existing brain metastases; history of inflammatory bowel disease
and/or acute/subacute bowel obstruction; serious non-healing
wound or ulcer; evidence of bleeding diathesis or coagulopathy;
uncontrolled hypertension; active clinically significant cardio-
vascular disease, for example, cerebrovascular accidents (p6
months), myocardial infarction (p6 months), unstable angina,
New York Heart Association grade II or greater congestive heart
failure, serious cardiac arrhythmia requiring medication; treat-
ment with anticoagulants within the previous 10 days; chronic,
daily treatment with high-dose aspirin (4325mgday
 1) or other
medications known to predispose to gastrointestinal ulceration.
Other exclusion criteria were major surgical procedure, open
biopsy or significant traumatic injury in the previous 28 days,
or anticipated need for major surgery during the course of the
study. Patients with symptomatic peripheral neuropathy Xgrade 1
according the National Cancer Institute Common Toxicity Criteria
(NCI-CTC) were excluded.
Statistical considerations
Primary end point of the study was the percentage of patients
amenable to complete resection after chemotherapy. The sample
size was calculated on the basis of the two-stage design by Simon.
Assuming that the standard resectability rate for liver metastases
was 18%, we planned to detect an increase in the resectability rate
of up to 33%. Therefore, a total of 46 patients were needed to
provide a power of 80% and an a-error equal to 5%. Sixteen
patients were planned for the first stage and another 30 patients to
be enrolled during the second stage. If three or fewer R0 surgical
resections were performed during the first stage, then the trial
would be stopped. The study would also be discontinued if we
observed a 430% adverse event rate (major wound healing
complications, haemorrhage, gastrointestinal perforation, fistula
and abscess) after surgery.
Secondary end points were: the incidence of postoperative
complications within 60 days of surgery; antitumor activity in
terms of overall response rate (complete and PRs); toxicity and
tolerability of the combination; time to progression (TTP) and OS.
In addition, the predictive value of PET-CT for response to
neoadjuvant treatment was investigated.
Overall response was defined as the best response recorded from
the start of treatment until disease progression. Stable disease (SD)
was measured from the start of the treatment until criteria for
disease progression were met. Time to progression was calculated
from the first day of treatment until progression, death from any
cause or last patient contact was to be known progression free or
alive. In patients undergoing surgery after experiencing sufficient
tumour shrinkage, any relapse, new occurrence of colorectal
cancer or death was treated as events. Time to treatment failure
(TTF) was calculated from the first day of treatment to the first
occurrence of premature withdrawal due to adverse events,
insufficient therapeutic response, death, failure to report, refusal
of treatment, uncooperativeness or withdrawal of consent. OS was
calculated from the first day of treatment to the date of death from
any cause or the last date the patient was known to be alive.
Treatment
The treatment schedule was: FOLFOX6 (oxaliplatin 100mgm
 2
on day 1, folinic acid 200mgm
 2 on day 1 and 5-fluorouracil
400mgm
 2 by 2-h i.v. bolus on day 1, followed by 3000mgm
 2 by
46-h continuous infusion starting on day 1) every 2 weeks for six
cycles and bevacizumab 5mgkg
 1 on day 1 every 2 weeks for five
cycles.
After the first 3 months of treatment, patients were evaluated for
resectability: surgery was performed at least 8 weeks after the last
dose of bevacizumab and 4 weeks after the last dose of
chemotherapy. Resection had to be complete and macroscopically
curative (R0). Radical surgery was defined as a margin of at least
1mm. Other surgical treatments permitted were a two-stage
hepatectomy; portal vein occlusion before major liver resection;
and combined approach of radiofrequency (RFA) and hepatic
resection. Patients undergoing intraoperative RFA were considered
among those patients treated with radical intent. All patients
treated with intraoperative RFA had lesions o3cm.
Patients with non-resectable PR or SD after the first 6 cycles
received 6 additional cycles of FOLFOX6þbevacizumab and were
then re-evaluated for surgery.
After surgery, six additional courses of FOLFOX6þ
bevacizumab were administered to those patients operated on
after receiving only six courses of therapy. This treatment was
started 4–8 weeks after surgery, following functional evaluation of
liver reserve and healing of surgical wounds. Postsurgical
abdominal abscesses were considered major postsurgical compli-
cations, whereas wound-healing delays were treated as minor
complications. Patients were evaluated by a multidisciplinary team
composed of an oncologist, radiologist and surgeon at diagnosis,
and again after 6 and 12 treatment cycles.
Toxicity and dose modifications
The intensity of clinical adverse events was graded according to the
NCI-CTC Version 3.0. In case of serious bevacizumab-related
toxicity, bevacizumab treatment was temporarily suspended.
Patients were excluded from receiving further treatment with
bevacizumab, if they developed at least one of the following
attributable toxicities: gastrointestinal perforation, arterial throm-
boembolic events, grade 3/4 haemorrhagic events, symptomatic
grade 4 thrombosis, grade 4 hypertension or grade 4 proteinuria.
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continued FOLFOX6 therapy on the planned schedule.
If a toxicity (haematological or gastrointestinal) was considered
to be primarily attributable to chemotherapy and occurred at
gradeX2, chemotherapy was discontinued until toxicity resolved
to grade 0–1 before restarting. If toxicity required a dosing delay
of all study drugs for more than 3 weeks, the patient was
withdrawn from the study for toxicity.
If paraesthesia with pain or persistent functional impairment
were the only toxicities present at the next planned oxaliplatin
administration, only oxaliplatin treatment was delayed, whereas
administration of folinic acid, 5-fluorouracil and bevacizumab
could continue on schedule. If the neurological toxicity was still
present at the time of the next planned treatment cycle, oxaliplatin
was discontinued permanently. Folinic acid, 5-fluorouracil and
bevacizumab were then continued at the discretion of the
investigator.
RESULTS
Patients
Between September 2005 and July 2009, 21 patients were enrolled.
On the basis of slow accrual of patients, we closed enrolment at
21 patients (16 in the first stage and 5 in the second stage). All of
these patients had metastases only to the liver. The median size of
liver metastases was 6cm in longest diameter (range: 1–9.7cm).
Twenty patients received six biweekly cycles of FOLFOX6 and five
cycles of bevacizumab, and were then evaluated for resectability.
A PET-CT was performed both at baseline and within 1 month
from the start of neoadjuvant therapy in 16 patients. Median time
from last dose of chemotherapy to surgery was 8.8 weeks and from
the last dose of bevacizumab to surgery was 10.8 weeks. Patient
characteristics are summarised in Table 1.
Toxicity
The main grade 3–4 toxicities reported were: neutropenia (19%),
including one neutropenic fever resulting in death from sepsis,
and thrombotic complications (14.3%). Haematological toxicity
was likely due to chemotherapy, whereas the thrombotic side
effects were due to bevacizumab. One patient discontinued
FOLFOX6þbevacizumab after 4 cycles for gastrointestinal and
haematological toxicity (grade 3). One patient received only one
administration of bevacizumab because of a grade 3 thrombotic
event and another received only four administrations due to
a grade 1 haemorrhagic event.
Grade 1–2 and 3–4 adverse events according to NCI-CTC
(version 3.0) are shown in Table 2.
Evaluation of response
After the first 3 months of treatment, 12 patients (57.1%)
experienced an OR (clinical CRs (cCRs): 3, 14.3%; PR: 9, 42.8%),
documented by RECIST criteria, and 20 patients had disease
control (95.2%). Among radiological CRs, one patient achieved a
radiological CR, but died from toxicity (sepsis in neutropenic
fever) before surgery. One patient diagnosed with rectal cancer
(12cm from anal rima) and a single synchronous liver metastasis
was evaluated as having SD by RECIST criteria, but analysis of the
resected lesion did not reveal neoplastic cells. He had undergone
surgery for the primary tumour, received medical treatment for
3 months and was then operated on for the liver metastasis.
PET-CT analysis
Sixteen patients had a PET-CT scan before starting treatment and
then again within 1 month of initiating treatment. Median SUVmax
at baseline was 8. There were 11 patients with SUVmax X8a t
baseline. Among these 11 patients, we observed 2 cCRs (18 %), 5 PR
(45.6%), 3 SD (27.4%) and 1 progressive disease (PD) (9%). Five
patients had SUVmax values o8 at baseline. Among these, we
observed one CR (20%), three PR (60%) and one SD (20%). Radical
surgery was possible in 9 of the 11 patients (81.8%) who had basal
SUVmax values X8 (3 with CRs underwent biopsy to confirm pCR,
4 had PR, and 2 with SD underwent liver resection), whereas only 1
patient with basal SUVmax value o8 underwent surgery for CLM
(P¼0.909). Moreover after the first cycle of therapy, the median
SUVmax was 5.2 (range: 0–8). Twelve patients had a reduction of
SUVmax by at least 1 unit. The absolute value of variation was not
detectable because it was not possible to measure SUVmax in all
patients. Patients who experienced a SUVmax reduction had longer
PFS (median PFS): 22 vs 14 months, P¼0.0010). No correlation was
found with OR or OS.
Table 1 Patient characteristics
(N¼21) %
Median age, years: 61 (range, 37–72)
Sex
Male 16 76
Female 5 24
ECOG
02 0 9 5
11 5
TN clinical stage
T1N0 1 4, 8
T2N0 1 4, 8
T3N0 3 14, 3
T3N1 6 28, 6
T3N2 5 23, 8
T4N1 4 19
No. of liver metastases
1–3 9 42, 9
4–5 1 4, 7
45 11 52, 4
CEA (ngml
 1)N ¼20
p55 2 5
451 5 7 5
CA 19, 9 (Uml
 1)N ¼20
p37 7 35
437 13 65
Table 2 Toxicity (first 6 cycles)
Toxicity (n¼ 21) G 1–2 (%) G 3–4 (%) Total (%)
Hematological toxicity
Neutropenia 4 (19) 4 (19) 8 (38)
Febrile neutropenia 0 (0) 1 (4.7) 1 (4.7)
Thrombocytopenia 1 (4.7) 0 (0) 1 (4.7)
Gastrointestinal toxicity
Diarrhea 4 (19) 1 (4.7) 5 (23.7)
Nausea/vomiting 3 (14.3) 1 (4.7) 4 (19)
Mucositis 2 (9.5) 0 (0) 2 (9.5)
Infection of central venous catheter 0 (0) 1 (4.7) 1 (4.7)
Hypertension 1 (4.7) 0 (0) 1 (4.7)
Proteinuria 0 (0) 0 (0) 0 (0)
Thrombosis 0 (0) 3 (14.3) 3 (14.3)
Rectal bleeding 1 (4.7) 0 (0) 1 (4.7)
Paresthesia 2 (9.5) 0 (0) 2 (9.5)
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Fourteen patients underwent surgery (66.6%): 13 had radical
surgery (61.9%), whereas 1 patient underwent only explorative
laparoscopy with no resection of the major liver involvement
(4.7%). Twelve patients were operated on after six cycles and one
patient after 12 cycles. Median time from the end of neoadjuvant
therapy (FOLFOX6) to surgery was 8.8 weeks. Of the 14 patients
who underwent surgery, 8 underwent only surgery (57.1), whereas
4 had surgery after portal vein embolisation, 1 had surgery with
RFA and 1 patient had surgery with both portal vein embolisation
and RFA.
In three cases, we documented a pCR (23%) on histological
examination. Six patients (46%) experienced postsurgical compli-
cations: three patients had abdominal abscesses (major: 23%)
and three had a delay in wound healing (minor: 23%). No
postoperative mortality was recorded (defined as death within
60 days of surgery). Median time from surgery to commence-
ment of systemic postoperative treatment was 43 days (range:
36–73 days).
No correlation was found between response rate and resection
rate (P¼0.369), OS and number of liver metastases (p3 vs 4 3)
(P¼0.456), or between OS and response rate (P¼0.404). The
correlations with response in resected and non-resected patients
are shown in Table 3.
As of the November 2009, the median follow-up was 3.2 years.
Median OS was 22.5 months (range: 4.2–41.4 months) (Figure 1).
Median OS in surgical compared with medical patients was 35.6 vs
15.3 months, respectively (P¼0.009) (Figure 2). Median PFS was
12.9 months (range: 3.7–40.9 months) (Figure 3). Of the 14
resected patients, 7 relapsed (50%). Median disease-free survival
(time from radical surgery to relapse) was 8 months (range:
5.9–13.5 months). Eleven patients died: 10 from disease progres-
sion and 1 from toxicity (sepsis in neutropenic fever). All results
are reported in Table 4.
DISCUSSION
Neoadjuvant chemotherapy has been shown to downsize and
increase the resection rate of unresectable CLM by 13–20%
(Sharma et al, 2008). In the present study, we have shown that
preoperative treatment with FOLFOX6, in association with
bevacizumab, may convert 66.6% of patients with CLM from
non-optimally resectable to resectable disease status. The original
study was planned for 46 patients and we accrued only 21 patients
over a 4-year period. Our decision to close recruitment before
reaching the planned accrual was on the basis of difficulty in
recruiting eligible patients. Therefore, all conclusions have been on
the basis of smaller number of patients enrolled.
Table 3 Objective response and surgery
Resected (%) Not resected (%)
N (on 21) 13 (61.9) 8 (38.1)
CR 2 (15.4) 1 (12.5)
PR 5 (38.5) 4 (50)
SD 6 (46.1) 2 (25)
PD 0 (0) 1 (12.5)
Abbreviations: CR¼complete response; PD¼progressive disease; PR¼partial
response; SD¼stable disease.
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Table 4 Results
N %
Objective response 12/21 57.1
R0 resection 13/21 61.9
Major postoperative complications 3/14 23
Median (months) Range (months)
Time to progression 12.1 3.1–39.7
Time to treatment failure 11.9 1.1–36.1
Progression-free survival 12.9 3.7–40.9
Overall survival 22.5 4.2–41.4
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matter of investigation: the present study suggests that the
combination of FOLFOX6 with bevacizumab may be a very good
option both in terms of efficacy (resectability rate: 66.6%) and major
postoperative complications (23%). Moreover, the choice of the best
biological agent is still controversial: a study by Folprecht et al (2010)
showed that the use of cetuximab in combination with oxaliplatin- or
irinotecan-based neoadjuvant chemotherapy resulted in a 28%
increase in the resectability rate, with a stronger effect depending
on K-ras status. On the contrary, the activity of bevacizumab is
independent of K-ras status and, when used in combination with
neoadjuvant chemotherapy, has obtained a high rate of pCRs, 23% in
the present study and from 8 to 10% in recent reports (Ribero et al,
2007; Blazer et al, 2008; Gruenberger et al, 2008; Bouganim, 2009;
Malavasi et al, 2009; Otsuka et al, 2009; Zorzi et al, 2010).
Only 23% of our patients presented major postsurgical
complications in line with other reports, which also document
that the use of bevacizumab in neoadjuvant setting did not affect
complication rates when used with an interval of 45 weeks
between the last bevacizumab administration and surgery (Benoist
et al, 2006; Gruenberger et al, 2008; Kesmodel et al, 2008).
Our study did not demonstrate the correlation between response
rate and the resection rate (P¼0.369) reported by Folprecht et al
(2005), or the pathologic response (Chun et al, 2009). This may be
due to patient selection, that is, patients with initially ‘non-
optimally resectable’, but potentially resectable metastases and
patients whose tumours will never be resectable. In the first
scenario, chemotherapy should offer a shrinkage of CLM, resulting
in a higher resectability rate, whereas in the second scenario,
chemotherapy has the role of extending disease control and
maintaining quality of life. Moreover, we include in the definition
of ‘non-optimally resectable patients’ not only anatomic/surgical
criteria, but also criteria related to the correct timing of the
surgical approach to liver metastases (i.e., synchronous liver
metastases in patients with rectal cancer; 3 of 21 patients).
In addition, we investigated the role of PET-CT in detecting
early responders to neoadjuvant treatment. Although the number
of patients was small, the observed reduction in SUVmax
(reduction of at least 1 unit) of FDG uptake does not seem to
predict response (P¼0.611) or resectability rate (P¼0.909).
However, patients who experienced a SUVmax reduction did have
longer PFS (median PFS: 22 vs 14 months, P¼0.0010). No
correlation was found with OS.
In terms of outcome, there was no correlation between OS and
the number of liver metastases (p3 vs 4 3) (P¼0.456), or
between OS and response rate (P¼0.404). Patients submitted to
surgery survived longer: 15.3 vs 35.6 months (P¼0.009). The
present study confirms the importance of chemotherapy in
association with surgery for CLM: for example, the results of a
recent study by the European Organization for Research and
Treatment of Cancer (EORTC, protocol 40983) suggests a 9.2%
improvement in 3-year PFS in patients with potentially resectable
liver disease who received perioperative chemotherapy as com-
pared with surgery alone (Nordlinger et al, 2008).
In conclusion, administration of FOLFOX6þbevacizumab in
this setting is feasible, does not increase the rate of major
postsurgical complications, and therefore does not delay the
resumption of chemotherapy after hepatic surgery. The correct
definition of ‘resectability’ is still controversial, not only regarding
anatomic/surgical criteria, but also regarding definition of the
correct timing of primary tumour and hepatic surgery.
Early changes in PET-CT, in particular, reduction of SUVmax,
seem to be a predictor of longer PFS, though the role of PET-CT
should be validated in a wider setting.
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